These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 22570359)

  • 1. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
    Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW;
    J Neurol Sci; 2010 May; 292(1-2):28-35. PubMed ID: 20236661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
    Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
    Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.
    Putzki N; Kollia K; Woods S; Igwe E; Diener HC; Limmroth V
    Eur J Neurol; 2009 Mar; 16(3):424-6. PubMed ID: 19187261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low degree of cortical pathology is associated with benign course of multiple sclerosis.
    Calabrese M; Favaretto A; Poretto V; Romualdi C; Rinaldi F; Mattisi I; Morra A; Perini P; Gallo P
    Mult Scler; 2013 Jun; 19(7):904-11. PubMed ID: 23069877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortical lesion load associates with progression of disability in multiple sclerosis.
    Calabrese M; Poretto V; Favaretto A; Alessio S; Bernardi V; Romualdi C; Rinaldi F; Perini P; Gallo P
    Brain; 2012 Oct; 135(Pt 10):2952-61. PubMed ID: 23065788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
    O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
    Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative MRI and cerebrospinal fluid inflammatory mediators in Brazilian patients with relapsing-remitting multiple sclerosis before and after treatment with immunomodulators: a longitudinal study.
    Ruocco HH; Brandão CO; Farias AS; Oliveira C; Oliveira EC; Cendes F; Damasceno BP; Santos LM
    Neuroimmunomodulation; 2012; 19(5):277-82. PubMed ID: 22472803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.
    Gauthier SA; Glanz BI; Mandel M; Tsagkaropoulos A; Neema M; Stankiewicz J; Arora A; Duan Y; Liptak Z; Egorova S; Buckle GJ; Bakshi R; Guttmann CR; Khoury SJ; Weiner HL
    J Neurol Sci; 2009 Sep; 284(1-2):116-9. PubMed ID: 19428028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.